文献速递妇科

早期子宫浆液性癌患者的辅助治疗:一项多机构研究

Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
PubMed 文献 · Gynecol Oncol · 2022-10-13

这项多机构回顾性队列研究纳入737例FIGO IA-II期子宫浆液性癌术后患者,比较不同辅助治疗策略。辅助治疗与复发风险降低相关(p=0.04);与无辅助治疗相比,近距离放疗和近距离放疗联合化疗均改善无复发生存和总生存,单纯化疗也改善总生存。

要点

  • 737例早期子宫浆液性癌患者中75%为IA期,49%无肌层浸润,24%有淋巴血管间隙浸润。
  • 辅助治疗方式多样:22%无辅助治疗,17%单纯化疗,19%阴道残端近距离放疗,35%近距离放疗联合化疗,6%盆腔放疗。
  • 与无辅助治疗相比,近距离放疗和近距离放疗联合化疗均改善无复发生存和总生存,单纯化疗也改善总生存。

核心结论

  • 辅助治疗与仅观察相比与复发风险降低相关。
  • 阴道残端近距离放疗联合或不联合化疗与早期子宫浆液性癌患者生存结局改善相关。

研究设计与样本

  • 多机构回顾性队列研究,纳入737例FIGO IA-II期术后子宫浆液性癌或任何混合浆液/非浆液组织学患者,排除癌肉瘤。
  • 临床数据从当地医疗记录中提取,采用描述性统计、Fisher精确检验和Kruskal-Wallis检验分析人口学和临床特征,并进行单变量和多变量分析评估无复发生存和总生存。

主要发现

  • 多数患者为IA期(75%),其中49%无肌层浸润;仅164例(24%)肿瘤有淋巴血管间隙浸润。
  • 辅助治疗与复发风险降低显著相关(p=0.04)。
  • 与无辅助治疗相比,近距离放疗组无复发生存HR 0.59(95% CI 0.40-0.86),近距离放疗联合化疗组HR 0.65(95% CI 0.49-0.88)。
  • 与无辅助治疗相比,近距离放疗组总生存HR 0.53(95% CI 0.35-0.79),近距离放疗联合化疗组HR 0.49(95% CI 0.35-0.69)。
  • 与无辅助治疗相比,单纯化疗组总生存HR 0.55(95% CI 0.37-0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uterine serous carcinoma is a rare but aggressive subtype of endometrial adenocarcinoma. Our objective was to compare adjuvant treatment strategies for patients with early stage uterine serous carcinoma. METHODS: This multi-institutional, retrospective cohort study evaluated patients with early stage uterine serous carcinoma. Patients with FIGO Stage IA-II disease after surgery, whose tumors had serous or any mixed serous/non-serous histology were included. Patients with carcinosarcoma were excluded. Clinical data were abstracted from local medical records. Summary statistics, Fisher's exact, and Kruskal-Wallis tests were used to analyze demographic and clinical characteristics. Univariable and multivariable analyses were performed for recurrence-free and overall survival. RESULTS: There were 737 patients included. Most patients had Stage IA disease (75%), 49% of which had no myometrial invasion. Only 164 (24%) tumors had lymphatic/vascular space invasion. Adjuvant treatment varied: 22% received no adjuvant therapy, 17% had chemotherapy alone, 19% had cuff brachytherapy, 35% had cuff brachytherapy with chemotherapy, and 6% underwent pelvic radiation. Adjuvant treatment was significantly associated with a decreased risk of recurrence (p = 0.04). Compared with no adjuvant therapy, patients who received brachytherapy or brachytherapy/chemotherapy had improved recurrence-free survival (HR 0.59, 95% CI 0.40-0.86; HR 0.65, 95% CI 0.49-0.88, respectively) and overall survival (HR 0.53, 95% CI 0.35-0.79; HR 0.49, 95% CI 0.35-0.69, respectively). Improved survival with brachytherapy and brachytherapy/chemotherapy persisted on multivariable analyses. Chemotherapy alone was also associated with improved overall survival compared with no adjuvant treatment (HR 0.55, 95% CI 0.37-0.81). CONCLUSIONS: Adjuvant therapy was associated with a decreased risk of recurrence relative to observation alone. Adjuvant cuff brachytherapy with and without chemotherapy was associated with improved survival outcomes in patients with early stage uterine serous carcinoma.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kurnit KC, Nobre SP, Fellman BM, et al. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecol Oncol. 2022. PMID: 36243601. doi:10.1016/j.ygyno.2022.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。